Literature DB >> 10334895

Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.

S A Ahrendt1, C F Eisenberger, L Yip, A Rashid, J T Chow, H A Pitt, D Sidransky.   

Abstract

BACKGROUND: Cholangiocarcinoma is a frequent complication of primary sclerosing cholangitis and is a leading cause of mortality in patients with this disease. The tumor suppressor gene p16 is commonly inactivated in many neoplasms; however, the role of p16 in the pathogenesis of cholangiocarcinoma is unclear. Therefore, we examined the role of p16 inactivation in the pathogenesis of cholangiocarcinoma associated with primary sclerosing cholangitis.
MATERIALS AND METHODS: Paraffin-embedded sections from 10 patients who developed cholangiocarcinoma in the setting of primary sclerosing cholangitis were examined. Chromosomal loss at 9p21 was determined using microsatellite analysis. Methylation of a CpG island in the promoter region of the p16 gene was determined using methylation-specific polymerase chain reaction. p16 inactivation was also determined using immunohistochemistry.
RESULTS: Allelic loss at chromosome 9p21 was present in 9 of 10 tumors (90%). Methylation of the p16 promoter was present in 2 of the 8 tumors examined (25%). Four of seven tumors (57%) analyzed by immunohistochemistry demonstrated an absence of p16 nuclear staining.
CONCLUSIONS: Loss of chromosome 9p21 and inactivation of the p16 tumor suppressor gene are common events in primary sclerosing cholangitis-associated cholangiocarcinoma and may play a role in the high incidence of cholangiocarcinoma in patients with primary sclerosing cholangitis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334895     DOI: 10.1006/jsre.1999.5615

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  19 in total

1.  ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A.

Authors:  Steven P O'Hara; Patrick L Splinter; Christy E Trussoni; Maria J Lorenzo Pisarello; Lorena Loarca; Noah S Splinter; Bryce F Schutte; Nicholas F LaRusso
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

Review 2.  Genetic profiling of intrahepatic cholangiocarcinoma.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Curr Opin Gastroenterol       Date:  2012-05       Impact factor: 3.287

3.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

4.  Aberrant DNA methylation profile in cholangiocarcinoma.

Authors:  Li Huang; Gabriel Frampton; Li-Jian Liang; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 5.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

6.  Management and outcome in patients with Klatskin-mimicking lesions of the biliary tree.

Authors:  Dirk Uhlmann; Marcus Wiedmann; Frank Schmidt; Regine Kluge; Andrea Tannapfel; Frieder Berr; Johann Hauss; Helmut Witzigmann
Journal:  J Gastrointest Surg       Date:  2006 Sep-Oct       Impact factor: 3.452

Review 7.  Molecular pathogenesis of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

Review 8.  Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets.

Authors:  Dalbir S Sandhu; Abdirashid M Shire; Lewis R Roberts
Journal:  Liver Int       Date:  2007-11-21       Impact factor: 5.828

9.  INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma.

Authors:  Michael Vieth; Regine Schneider-Stock; Knut Röhrich; Andrea May; Christian Ell; Anett Markwarth; Albert Roessner; Manfred Stolte; Andrea Tannapfel
Journal:  Virchows Arch       Date:  2004-06-08       Impact factor: 4.064

10.  INK4a-ARF alterations in liver cell adenoma.

Authors:  A Tannapfel; C Busse; F Geissler; H Witzigmann; J Hauss; C Wittekind
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.